Prostate Cancer | Ready for Prime Time? Determining the Current and Future Role of PARP Inhibitor-Based Combinations in the Management of Prostate Cancer

Featuring perspectives from Dr Neeraj Agarwal, Dr Emmanuel S Antonarakis, Prof Karim Fizazi and Dr Susan F Slovin, including the following topics:

• Introduction: Current landscape of prostate cancer treatment (0:00)
• Relevance of homologous recombination repair mutations in castration-resistant prostate cancer: Treatment with PARP inhibitors as monotherapy — Dr Antonarakis (12:33)
• Phase III PROpel and MAGNITUDE trials — Dr Slovin (35:44)
• PARP inhibitor combination treatments for advanced prostate cancer — Dr Agarwal (57:08)
• Future directions in the use of PARP inhibitors for prostate cancer — Prof Fizazi (1:23:49)
• Journal Club (1:35:53)
• Case discussions (2:11:57)

CME information and select publications